Clinical Trials Browser

Recruiting × Observational × trastuzumab deruxtecan × Clear all

NCT06551220 2026-05-22

HEROIC

Breast Neoplasms

NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT05993234 2026-05-08

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Gastrointestinal

HER2-positive Advanced Gastric Cancer

NCT07124000 2026-05-01

DP-04

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT05945732 2026-02-12

DESTINY Breast Respond HER2-low Europe

Breast Neoplasms

NCT06210776 2026-01-12

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Breast Neoplasms

NCT07180264 2025-11-18

Trastuzumab Deruxtecan in Advanced Breast Cancer

Advanced Breast Cancer

NCT06846996 2025-07-08

RECOVER

Gastrointestinal

HER2-positive Gastric Cancer

NCT06727227 2025-07-01

EXPLORE

Breast Neoplasms

NCT07030569 2025-06-22

RADIOSPHER2

Breast Neoplasms